#USA #San Diego #Class Action #Securities Fraud #Medpace Holdings

Medpace Holdings Inc. (MEDP) Class Action Lawsuit Alert

Investors who purchased shares of Medpace Holdings Inc. (NASDAQ: MEDP) between April 22, 2025, and February 9, 2026, are being urged by Robbins Geller Rudman & Dowd LLP to consider leading a class action lawsuit due to significant financial losses incurred during this period. The lawsuit, filed under the caption Durbin v. Medpace Holdings Inc., alleges that the company and its top executives committed violations of the Securities Exchange Act of 1934.

Key Details of the Case

The legal action stems from multiple misleading statements made by Medpace during the class period regarding its business prospects and financial health. Specifically, the lawsuit claims:

• - Medpace's projections for its book-to-bill ratio for Q4 2025 were consistently overstated.
• - The company failed to adequately disclose the implications of cancellations on these ratios.
• - Management reassured investors that their forecasts were reasonable, dismissing concerns about a weakening business environment.

On February 9, 2026, Medpace released its earnings for the fourth quarter, revealing a disappointing book-to-bill ratio of 1.04, which was significantly lower than previously communicated guidance. Following this announcement, Medpace’s stock price plummeted by nearly 16%, reflecting the negative impact of the news on investor confidence and market perception.

The Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 allows any investor who suffered losses during the designated class period to seek the role of lead plaintiff in the class action suit. The lead plaintiff's primary responsibility involves representing the interests of all class members in guiding the litigation process. Furthermore, choosing a law firm for legal representation is at the discretion of the lead plaintiff. It’s important to note that participation as a lead plaintiff does not determine an investor's eligibility for potential recovery in the case.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a well-respected law firm specializing in securities fraud and shareholder rights litigation. It has consistently ranked among the top law firms for recovering investor losses, with over $916 million recovered in 2025 alone. The firm is dedicated to advocating for investor rights and has achieved some of the largest securities class action recoveries in history. Recent statistics show that in the last five years, Robbins Geller has recovered an impressive $8.4 billion on behalf of investors, a testament to their expertise and commitment.

If you believe you are eligible to participate in the class action or want more information, Robbins Geller encourages you to visit their case information page here or reach out via contact details provided on their website.

Investors should be proactive and seek advice to understand their rights and options following the developments surrounding Medpace Holdings, as timely actions can significantly impact recovery potential.